A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 492 participants.
Also called NCT06926660
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 492 participants
- Sponsor
- Registry
-
NCT06926660 -
2024-518457-42-00 -
U1111-1314-0083
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Argentina, Australia, Belgium, Brazil, Canada, China, Czechia, France, Germany, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Philippines, Poland, Puerto Rico, South Korea, Spain, Taiwan, Thailand, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT06926660. Randomized; quadruple masking; primary purpose treatment. Start 2025-07-18 (actual); primary completion 2026-08-14 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- Vicadrostat
- Intervention (Drug)
- Empagliflozin
- Intervention (Drug)
- Placebo matching vicadrostat
- Lead sponsor
- Boehringer Ingelheim
Record details
- Record id
cardio:ct-nct06926660- Content hash
57beea4d66fe6d580af3de78f6e0e3c74d74d2ef0a318c1b75471a91706b06cf